^
    Back
    Association details:
    Biomarker:KRAS amplification
    Cancer:Melanoma
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Clin Cancer Res
    Title:

    Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma

    Published date:
    08/27/2015
    Excerpt:
    CPS therapy was associated with improved overall survival (OS) compared with CP in patients with tumors with KRAS gene copy gains (HR, 0.25; P = 0.035).
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1158/1078-0432.CCR-15-1162